These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9142971)

  • 1. Efficacy of pamidronate in breast cancer with bone metastases: a randomized double-blind placebo controlled multicenter study.
    Hultborn R; Gundersen S; Rydén S; Holmberg E; Carstensen J; Wallgren UB; Kilany S
    Acta Oncol; 1996; 35 Suppl 5():73-4. PubMed ID: 9142971
    [No Abstract]   [Full Text] [Related]  

  • 2. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials.
    Lipton A; Theriault RL; Hortobagyi GN; Simeone J; Knight RD; Mellars K; Reitsma DJ; Heffernan M; Seaman JJ
    Cancer; 2000 Mar; 88(5):1082-90. PubMed ID: 10699899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study.
    Hultborn R; Gundersen S; Ryden S; Holmberg E; Carstensen J; Wallgren UB; Killany S; Andreassen L; Carlsson G; Fahl N; Hatschek T; Sommer HH; Hessman Y; Hornmark-Stenstam B; Johnsborg S; Klepp R; Laino R; Niklasson LG; Rudenstam CM; Sundbeck A; Söderberg M; Tejler G
    Anticancer Res; 1999; 19(4C):3383-92. PubMed ID: 10629624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How can we improve the treatment of bone metastases further?
    Coleman RE
    Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S7-13. PubMed ID: 9801853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in the treatment and palliation of advanced breast cancer: does the dose of pamidronate determine its effects?
    Thürlimann B
    Ann Oncol; 1994; 5 Suppl 7():S45-7. PubMed ID: 7532993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
    Jacobs C; Kuchuk I; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Dranitsaris G; Dent S; Gertler S; Verma S; Song X; Simos S; Cella D; Clemons M
    Breast Cancer Res Treat; 2016 Jan; 155(1):77-84. PubMed ID: 26643085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates for breast cancer.
    Pavlakis N; Stockler M
    Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study.
    Glover D; Lipton A; Keller A; Miller AA; Browning S; Fram RJ; George S; Zelenakas K; Macerata RS; Seaman JJ
    Cancer; 1994 Dec; 74(11):2949-55. PubMed ID: 7525038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonate treatment of lytic bone metastases.
    Lipton A; Berenson JR
    Drugs Aging; 1999 Apr; 14(4):241-6. PubMed ID: 10319239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of bisphosphonates in cancer patients.
    Body JJ; Coleman RE; Piccart M
    Cancer Treat Rev; 1996 Jul; 22(4):265-87. PubMed ID: 9025784
    [No Abstract]   [Full Text] [Related]  

  • 11. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.
    Small EJ; Smith MR; Seaman JJ; Petrone S; Kowalski MO
    J Clin Oncol; 2003 Dec; 21(23):4277-84. PubMed ID: 14581438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fitting new modalities into practice guidelines.
    Theriault RL
    Oncology (Williston Park); 1997 Nov; 11(11A):145-9. PubMed ID: 9430184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy.
    Body JJ; Dumon JC; Gineyts E; Delmas PD
    Br J Cancer; 1997; 75(3):408-12. PubMed ID: 9020487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.
    Hortobagyi GN; Theriault RL; Porter L; Blayney D; Lipton A; Sinoff C; Wheeler H; Simeone JF; Seaman J; Knight RD
    N Engl J Med; 1996 Dec; 335(24):1785-91. PubMed ID: 8965890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pamidronate infusions as single-agent therapy for bone metastases: a phase II trial in patients with breast cancer.
    Tyrrell CT; Bruning PF; May-Levin F; Rose C; Mauriac L; Soukop M; Ford JM
    Eur J Cancer; 1995 Nov; 31A(12):1976-80. PubMed ID: 8562151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Biosphonates in oncology].
    Paule B; Clerc D; Brion N
    Presse Med; 2000 Apr; 29(13):723-9. PubMed ID: 10797827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma.
    Morton AR; Cantrill JA; Pillai GV; McMahon A; Anderson DC; Howell A
    BMJ; 1988 Sep; 297(6651):772-3. PubMed ID: 3142542
    [No Abstract]   [Full Text] [Related]  

  • 18. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.
    Rosen LS; Gordon DH; Dugan W; Major P; Eisenberg PD; Provencher L; Kaminski M; Simeone J; Seaman J; Chen BL; Coleman RE
    Cancer; 2004 Jan; 100(1):36-43. PubMed ID: 14692022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale for the use of bisphosphonates in breast cancer.
    Kanis JA
    Acta Oncol; 1996; 35 Suppl 5():61-7. PubMed ID: 9142969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
    Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.